Clinical Trials
64 trialsEfficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
EREMISS
Centre Oscar Lambret
REGO-SARC
Centre Oscar Lambret
REBECCA
Centre Oscar Lambret
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
DREAM
First Affiliated Hospital, Sun Yat-Sen University
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
REGOMA-2
Istituto Oncologico Veneto IRCCS
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Massachusetts General Hospital
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
RePERSO
Rennes University Hospital
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
a-MANTRA
Gruppo Oncologico Italiano di Ricerca Clinica
REGONIVO
National Cancer Center Hospital East
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Asan Medical Center
Regorafenib in Metastatic Colorectal Cancer
University of Rochester
GOING
Fundacion Clinic per a la Recerca Biomédica
Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS
Istituto Oncologico Veneto IRCCS
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
SCRI Development Innovations, LLC
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
REGOVAR
ARCAGY/ GINECO GROUP
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Stanford University
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Hunan Cancer Hospital
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
RENOBATE
Asan Medical Center
RESOUND
Istituto Clinico Humanitas
REGOMA
Istituto Oncologico Veneto IRCCS
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
National Cancer Centre, Singapore
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Northwestern University
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Wake Forest University Health Sciences
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
SURE
Dana-Farber Cancer Institute
PROSPECT-R
Royal Marsden NHS Foundation Trust
Regorafenib and Cetuximab in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
REMETY
AIO-Studien-gGmbH
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
University of Alabama at Birmingham
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
RE-ARRANGE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)